{
    "organizations": [],
    "uuid": "751a7ed5466394d0a10c8c9a003f30eb15c9df2b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-psivida-announces-acquisition-of-i/brief-psivida-announces-acquisition-of-icon-bioscience-financing-agreements-idUSL8N1RA79K",
    "ord_in_thread": 0,
    "title": "BRIEF-pSivida announces Acquisition Of Icon Bioscience, financing agreements",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - pSivida Corp:\n* PSIVIDA CORP. ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC. AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS â€“ COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS, INC.\n* EW HEALTHCARE & THIRD PARTY INVESTOR TO MAKE INVESTMENT IN CO OF UP TO ABOUT $60.5 MILLION\n* SWK HOLDINGS WILL PROVIDE UP TO $20 MILLION IN DEBT FINANCING\n* PSIVIDA CORP. WILL REBRAND AND CHANGE ITS NAME TO EYEPOINT PHARMACEUTICALS INC.\n* ENTERED INTO A FINANCIAL AGREEMENT WITH EW HEALTHCARE PARTNERS\n* EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE EQUITY INVESTMENTS IN PSIVIDA\n* WILL USE FUNDS TO FINANCE ICON ACQUISITION AND PREPARE FOR COMMERCIAL LAUNCHES OF DEXYCU\n* IF APPROVED, PSIVIDA EXPECTS TO LAUNCH DURASERT IN U.S. IN FIRST HALF OF 2019\n* PSIVIDA PLANS TO LAUNCH DEXYCU IN U.S. IN FIRST HALF OF 2019\n* EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE AN EQUITY INVESTMENT IN PSIVIDA FOR UP TO ABOUT $60.5 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-29T00:22:00.000+03:00",
    "crawled": "2018-03-29T00:32:59.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "psivida",
        "corp",
        "psivida",
        "announces",
        "transformative",
        "acquisition",
        "icon",
        "bioscience",
        "growth",
        "capital",
        "financing",
        "essex",
        "woodland",
        "healthcare",
        "partner",
        "company",
        "rebrand",
        "eyepoint",
        "pharmaceutical",
        "ew",
        "healthcare",
        "third",
        "party",
        "investor",
        "make",
        "investment",
        "co",
        "million",
        "swk",
        "holding",
        "provide",
        "million",
        "debt",
        "financing",
        "psivida",
        "rebrand",
        "change",
        "name",
        "eyepoint",
        "pharmaceutical",
        "entered",
        "financial",
        "agreement",
        "ew",
        "healthcare",
        "partner",
        "ew",
        "healthcare",
        "partner",
        "third",
        "party",
        "investor",
        "make",
        "equity",
        "investment",
        "psivida",
        "use",
        "fund",
        "finance",
        "icon",
        "acquisition",
        "prepare",
        "commercial",
        "launch",
        "dexycu",
        "approved",
        "psivida",
        "expects",
        "launch",
        "durasert",
        "first",
        "half",
        "psivida",
        "plan",
        "launch",
        "dexycu",
        "first",
        "half",
        "ew",
        "healthcare",
        "partner",
        "third",
        "party",
        "investor",
        "make",
        "equity",
        "investment",
        "psivida",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}